Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.

Stone AM, Bushnell W, Denne J, Sargent DJ, Amit O, Chen C, Bailey-Iacona R, Helterbrand J, Williams G; PhRMA working group.

Eur J Cancer. 2011 Aug;47(12):1763-71. doi: 10.1016/j.ejca.2011.02.011. Epub 2011 Mar 22.

PMID:
21435858
2.

Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis.

Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, Burger HU.

Eur J Cancer. 2011 Aug;47(12):1772-8. doi: 10.1016/j.ejca.2011.02.013. Epub 2011 Mar 21.

PMID:
21429737
3.

Two-stage randomization designs in drug development.

Wolbers M, Helterbrand JD.

Stat Med. 2008 Sep 20;27(21):4161-74. doi: 10.1002/sim.3309.

PMID:
18570274
4.

Cox regression methods for two-stage randomization designs.

Lokhnygina Y, Helterbrand JD.

Biometrics. 2007 Jun;63(2):422-8. Epub 2007 Apr 9.

PMID:
17425633
5.

Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei.

LaRosa SP, Opal SM, Utterback B, Yan SC, Helterbrand J, Simpson AJ, Chaowagul W, White NJ, Fisher CJ Jr.

Int J Infect Dis. 2006 Jan;10(1):25-31. Epub 2005 Nov 11.

6.

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

Crit Care Med. 2004 Nov;32(11):2199-206.

7.

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.

PMID:
12544987
8.

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis.

Macias WL, Dhainaut JF, Yan SC, Helterbrand JD, Seger M, Johnson G 3rd, Small DS.

Clin Pharmacol Ther. 2002 Oct;72(4):391-402.

PMID:
12386641
9.

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis.

Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE Jr, Russell JA, Mayers I, Rosenfeld BA, Morris PE, Yan SB, Helterbrand JD.

Crit Care Med. 2001 Nov;29(11):2051-9.

PMID:
11700394
10.

Low levels of protein C are associated with poor outcome in severe sepsis.

Yan SB, Helterbrand JD, Hartman DL, Wright TJ, Bernard GR.

Chest. 2001 Sep;120(3):915-22.

PMID:
11555529
11.

Design and methods of the Raloxifene Use for The Heart (RUTH) study.

Mosca L, Barrett-Connor E, Wenger NK, Collins P, Grady D, Kornitzer M, Moscarelli E, Paul S, Wright TJ, Helterbrand JD, Anderson PW.

Am J Cardiol. 2001 Aug 15;88(4):392-5.

PMID:
11545760
12.

Efficacy and safety of recombinant human activated protein C for severe sepsis.

Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.

N Engl J Med. 2001 Mar 8;344(10):699-709.

13.

Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.

Mesters RM, Helterbrand J, Utterback BG, Yan B, Chao YB, Fernandez JA, Griffin JH, Hartman DL.

Crit Care Med. 2000 Jul;28(7):2209-16.

PMID:
10921542
14.

Application of automatic image segmentation to tibiae and vertebrae from ovariectomized rats.

Helterbrand JD, Higgs RE Jr, Iversen PW, Tysarczyk-Niemeyer G, Sato M.

Bone. 1997 Nov;21(5):401-9.

PMID:
9356733
15.

Advantages of raloxifene over alendronate or estrogen on nonreproductive and reproductive tissues in the long-term dosing of ovariectomized rats.

Sato M, Bryant HU, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Turner CH, Owan I, Takano Y, Burr DB.

J Pharmacol Exp Ther. 1996 Oct;279(1):298-305.

PMID:
8859007
16.

One-pixel-wide closed boundary identification.

Helterbrand JD.

IEEE Trans Image Process. 1996;5(5):780-3.

PMID:
18285168

Supplemental Content

Loading ...
Support Center